Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFMD
LFMD logo

LFMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.800
Open
4.510
VWAP
4.68
Vol
840.91K
Mkt Cap
231.17M
Low
4.460
Amount
3.94M
EV/EBITDA(TTM)
--
Total Shares
48.36M
EV
196.69M
EV/OCF(TTM)
--
P/S(TTM)
1.14
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
Show More

Events Timeline

(ET)
2026-05-06
17:10:00
LifeMD Q1 Revenue Exceeds $50.2 Million
select
2026-05-06
17:10:00
LifeMD Reports Q1 Revenue of $50.16M, Beating Consensus
select
2026-05-06
17:10:00
Sees Q2 Adjusted EBITDA Loss of $2M to Gain of $1M
select
2026-04-10 (ET)
2026-04-10
08:30:00
LifeMD Launches Eli Lilly's Foundayo for Weight Management
select
2026-03-31 (ET)
2026-03-31
09:00:00
LifeMD Launches Novo Nordisk Wegovy Subscription Program, Patients Save Up to $1,200
select
2026-03-31
07:50:00
Novo Nordisk Launches Wegovy Subscription Program, Save Up to $1200 Annually
select

News

seekingalpha
9.5
05-07seekingalpha
LifeMD Reports Strong Q1 2026 Earnings with Record Subscriber Growth
  • Significant Revenue Growth: LifeMD reported revenue of $50.2 million in Q1 2026, exceeding guidance, while adding over 42,000 net telehealth subscribers, marking the largest quarterly increase in its history, indicating strong market performance and sustained customer demand.
  • Surge in Weight Management Patients: The number of sign-ups in weight management increased approximately 120% sequentially from Q4, reaching nearly 100,000 patients, demonstrating rapid expansion in this segment and enhanced customer attraction.
  • Gross Margin Improvement: The gross margin for the quarter expanded by approximately 420 basis points to 88%, with gross profit at $44.2 million, reflecting successful operational efficiency and cost control, thereby strengthening the foundation for future profitability.
  • Optimistic Future Outlook: Management reaffirmed full-year revenue guidance of $220 million to $230 million, with expected adjusted EBITDA exceeding $25 million by Q4, showcasing confidence in future growth and clarity in strategic planning.
seekingalpha
9.5
05-06seekingalpha
LifeMD Q1 Earnings Beat Expectations with Revenue Growth
  • Earnings Highlights: LifeMD reported a Q1 GAAP EPS of -$0.20, beating expectations by $0.03, indicating potential improvements in profitability.
  • Revenue Performance: The company generated $50.2 million in revenue for Q1, a 23.6% year-over-year decline, yet it surpassed market expectations by $1.32 million, demonstrating resilience in a challenging market.
  • Gross Margin Expansion: Gross profit rose by 3% to $44.2 million, with gross margin expanding from 84% to 88% year-over-year, primarily due to an optimized product mix, showcasing effective cost management and pricing strategies.
  • Increased Marketing Spend: Selling and marketing expenses surged by 34% to $29.9 million, reflecting strategic investments in front-loaded patient acquisition aimed at driving accelerated growth in the upcoming quarters.
CNBC
8.5
05-04CNBC
LifeMD's Business Doubles Following Wegovy Pill Launch
  • Significant Business Growth: Following the launch of the Wegovy pill, LifeMD experienced a surge in daily new patients from 300-400 to 600-1,000, indicating strong market demand for oral GLP-1 medications and solidifying its position in telehealth.
  • Intensified Market Competition: The successful introduction of Novo Nordisk's Wegovy pill in the U.S. has forced investors to reassess the market potential for oral GLP-1 drugs, particularly after Eli Lilly's Foundayo launch, which has shown a more modest market response, highlighting Novo's competitive edge.
  • Increased Patient Acceptance: The lower price and efficacy of the Wegovy pill have led to a growing preference for oral medications over injections, with a notable increase in male patients, which not only expands the GLP-1 market reach but also potentially brings in a more diverse patient demographic.
  • Uncertain Future Outlook: Despite the strong performance of Novo's Wegovy pill, analysts remain pessimistic about future sales and profit forecasts, expecting a decline of 5% to 13% by 2026, which could impact investor confidence and pose challenges for the company's long-term growth.
Newsfilter
5.0
04-10Newsfilter
LifeMD Launches Foundayo to Enhance Obesity Management Services
  • New Drug Launch: LifeMD has officially launched Foundayo (orforglipron), an oral medication developed by Eli Lilly, providing a once-daily treatment option for adults with obesity or overweight, marking a significant expansion in the company's obesity management offerings.
  • Pricing and Insurance: The self-pay starting price for Foundayo is $149 per month, while eligible patients with commercial insurance can pay as little as $25 per month through a Lilly savings card, with Medicare coverage expected to begin in July 2026, significantly reducing the financial burden on patients.
  • Integrated Services: By integrating with LillyDirect, LifeMD can offer direct prescription fulfillment and shipping to patients, ensuring quick and convenient access to treatment, which enhances service efficiency and patient satisfaction.
  • Market Positioning: The launch of Foundayo not only expands LifeMD's portfolio of GLP-1 therapies but also reinforces its leadership position in clinically guided obesity management, demonstrating the company's commitment to providing high-quality, affordable healthcare services.
CNBC
8.5
03-31CNBC
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
  • Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
  • Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
  • Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
  • Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
seekingalpha
5.0
03-16seekingalpha
LifeMD Appoints New CFO, Shares Rise 7%
  • Executive Change: LifeMD appointed Atul Kavthekar as CFO effective March 16, replacing Marc Benathen, who will remain until March 31, 2026, to ensure a smooth leadership transition, highlighting the company's commitment to stability in its executive team.
  • Stock Surge: Following the announcement, LifeMD shares rose nearly 7% in premarket trading, reflecting market confidence in the new CFO and optimistic expectations for the company's future growth trajectory.
  • Financial Targets: LifeMD outlined a target of over $250 million in annualized revenue run rate by Q4 2026, driven by record demand for GLP-1 drugs and expanded partnerships, indicating the company's strategy to capitalize on a rapidly growing market.
  • Analyst Rating: Cantor Fitzgerald reiterated its Overweight rating on LifeMD after the company reported strong Q4 results, demonstrating analysts' positive outlook on the company's future performance, which may further bolster investor confidence.
Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
Wall Street analysts forecast LFMD stock price to rise
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
6.00
Averages
9.67
High
15.00
Current: 0.000
sliders
Low
6.00
Averages
9.67
High
15.00
Mizuho
Neutral -> Outperform
upgrade
$6 -> $8
AI Analysis
2026-03-16
Reason
Mizuho
Price Target
$6 -> $8
AI Analysis
2026-03-16
upgrade
Neutral -> Outperform
Reason
Mizuho upgraded LifeMD to Outperform from Neutral with a price target of $8, up from $6. The firm cites the company's better than expected 2026 outlook for the upgrade. LifeMD continues to expand into new therapeutic areas for virtual care, but the investment thesis is still riven by the company's weight loss management program, the analyst tells investors in a research note. Mizuho sees the company's oral GLP-1 drugs "serving as the anchor" to drive patient growth in 2026 and beyond. It views LifeMD as a "portfolio" play on branded GLP-1s from both Eli Lilly and Novo Nordisk, "without having to decide which manufacturer will be the winner."
Freedom Capital
Buy
upgrade
$8 -> $10
2026-03-12
Reason
Freedom Capital
Price Target
$8 -> $10
2026-03-12
upgrade
Buy
Reason
Freedom Capital raised the firm's price target on LifeMD to $10 from $8 and keeps a Buy rating on the shares. The company's Q4 reported confirm a growth reacceleration as its revenue and adjusted EBITDA beat expectations, the analyst tells investors in a research note. The firm sees share upside from LifeMD's user-retention metrics.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFMD
Unlock Now

Valuation Metrics

The current forward P/E ratio for LifeMD Inc (LFMD.O) is 15.43, compared to its 5-year average forward P/E of -17.40. For a more detailed relative valuation and DCF analysis to assess LifeMD Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.40
Current PE
15.43
Overvalued PE
41.50
Undervalued PE
-76.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.57
Current EV/EBITDA
-20.52
Overvalued EV/EBITDA
18.34
Undervalued EV/EBITDA
-7.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.06
Current PS
0.83
Overvalued PS
1.65
Undervalued PS
0.48

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

pennie stocks to trade
Intellectia · 83 candidates
Price: $1.00 - $5.00Volume: >= 1,000,000Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA20, PriceAboveMA5, PriceCrossAboveMA5
Ticker
Name
Market Cap$
top bottom
RXT logo
RXT
Rackspace Technology Inc
565.74M
RDZN logo
RDZN
Roadzen Inc
146.58M
INO logo
INO
Inovio Pharmaceuticals Inc
101.17M
SABR logo
SABR
Sabre Corp
723.17M
ZVIA logo
ZVIA
Zevia PBC
91.54M
GENI logo
GENI
Genius Sports Ltd
1.13B
Day trading picks
Intellectia · 115 candidates
Price: $5.00 - $100.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMin5 Price Change Pct: $0.50 - $5.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
RGTI logo
RGTI
Rigetti Computing Inc
6.58B
RDW logo
RDW
Redwire Corp
2.06B
LUNR logo
LUNR
Intuitive Machines Inc
5.98B
DOW logo
DOW
Dow Inc
25.62B
AXTI logo
AXTI
AXT Inc
4.59B
SBET logo
SBET
Sharplink Inc
1.58B
sort by price
Intellectia · 16 candidates
Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
OTLK logo
OTLK
Outlook Therapeutics Inc
32.35M
TOVX logo
TOVX
Theriva Biologics Inc
11.80M
CANG logo
CANG
Cango Inc
198.55M
SILO logo
SILO
Silo Pharma Inc
8.38M
BLNK logo
BLNK
Blink Charging Co
99.60M
CUE logo
CUE
Cue Biopharma Inc
59.20M
cheapest top moving penny stocks
Intellectia · 16 candidates
Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
ENVB logo
ENVB
Enveric Biosciences Inc
4.44M
TOVX logo
TOVX
Theriva Biologics Inc
11.80M
CMND logo
CMND
Clearmind Medicine Inc
2.00M
CUE logo
CUE
Cue Biopharma Inc
59.20M
CANG logo
CANG
Cango Inc
198.55M
TCRX logo
TCRX
TScan Therapeutics Inc
67.71M
give me penny stocks
Intellectia · 42 candidates
Market Cap: 50.00M - 1000.00MRegion: USPrice: $0.50 - $5.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: $10.00 - $150.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
WTI logo
WTI
W&T Offshore Inc
446.33M
SABR logo
SABR
Sabre Corp
596.71M
SIDU logo
SIDU
Sidus Space Inc
188.92M
AIRS logo
AIRS
AirSculpt Technologies Inc
190.43M
NRGV logo
NRGV
Energy Vault Holdings Inc
636.55M
OLPX logo
OLPX
Olaplex Holdings Inc
890.31M
can you limit the choices to only 5 stocks
Intellectia · 724 candidates
Price: <= $10.00Pe Ttm: <= 15Target Price Upside Potential: MoreAbovePrice
Ticker
Name
Market Cap$
top bottom
FLUX logo
FLUX
Flux Power Holdings Inc
31.80M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
SGMO logo
SGMO
Sangamo Therapeutics Inc
127.97M
AQST logo
AQST
Aquestive Therapeutics Inc
409.93M
TRAW logo
TRAW
Traws Pharma Inc
19.42M
BTCS logo
BTCS
BTCS Inc
126.36M
pennystocks
Intellectia · 37 candidates
Market Cap: <= 300.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
ASPN logo
ASPN
Aspen Aerogels Inc
295.88M
SLQT logo
SLQT
SelectQuote Inc
283.31M
STTK logo
STTK
Shattuck Labs Inc
280.96M
AVIR logo
AVIR
Atea Pharmaceuticals Inc
275.01M
JELD logo
JELD
JELD-WEN Holding Inc
258.00M
TYGO logo
TYGO
Tigo Energy Inc
243.42M
inom den amerikanska marknaden
Intellectia · 15 candidates
Market Cap: <= 1.50BPrice: <= $25.00Beta: HighRiskRsi 14: <= 45Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
SG logo
SG
Sweetgreen Inc
820.33M
NVX logo
NVX
NOVONIX Ltd
222.62M
LFMD logo
LFMD
LifeMD Inc
170.40M
TMCI logo
TMCI
Treace Medical Concepts Inc
166.30M
HFFG logo
HFFG
Hf Foods Group Inc
116.17M
PYXS logo
PYXS
Pyxis Oncology Inc
103.36M
penny stocks wth great potential
Intellectia · 10 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Debt Equity: <= 0.500Weekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
LAB logo
LAB
Standard BioTools Inc
630.69M
NPWR logo
NPWR
NET Power Inc
575.35M
DGXX logo
DGXX
Digi Power X Inc
201.90M
LFMD logo
LFMD
LifeMD Inc
170.40M
TONX logo
TONX
Ton Strategy Co
163.68M
what penny stock to invest in
Intellectia · 12 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Debt Equity: <= 1Weekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
IOVA logo
IOVA
Iovance Biotherapeutics Inc
996.39M
LAB logo
LAB
Standard BioTools Inc
630.69M
NPWR logo
NPWR
NET Power Inc
575.35M
DGXX logo
DGXX
Digi Power X Inc
201.90M
LFMD logo
LFMD
LifeMD Inc
170.40M
TONX logo
TONX
Ton Strategy Co
163.68M

Whales Holding LFMD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is LifeMD Inc (LFMD) stock price today?

The current price of LFMD is 4.78 USD — it has increased 6.46

What is LifeMD Inc (LFMD)'s business?

LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.

What is the price predicton of LFMD Stock?

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is LifeMD Inc (LFMD)'s revenue for the last quarter?

LifeMD Inc revenue for the last quarter amounts to 50.16M USD, decreased -1.42

What is LifeMD Inc (LFMD)'s earnings per share (EPS) for the last quarter?

LifeMD Inc. EPS for the last quarter amounts to -0.20 USD, increased 900.00

How many employees does LifeMD Inc (LFMD). have?

LifeMD Inc (LFMD) has 347 emplpoyees as of May 10 2026.

What is LifeMD Inc (LFMD) market cap?

Today LFMD has the market capitalization of 231.17M USD.